Mertelsmann R, Herrmann F, Hecht T, Schulz G
Department of Medicine I, Albert-Ludwigs-University Medical Center, Freiburg, FRG.
Bone Marrow Transplant. 1990 Aug;6(2):73-7.
Preliminary clinical results demonstrate the activity of recombinant human granulocyte (rHuG) and granulocyte/macrophage (rHuGM) colony stimulating factors (CSFs) in enhancing bone marrow engraftment after autologous and allogeneic bone marrow transplantation (BMT). In several analyses of prospective, controlled clinical trials of rHuG- and rHuGM-CSF, reduced morbidity and cost, as well as improved survival have been observed. There is reason to hope that more profound understanding of the in vivo biology of these and other cytokines will lead to further reduction in morbidity and mortality associated with both autologous as well as allogeneic BMT. These advances could significantly broaden the spectrum of diseases amenable to treatment by BMT.
初步临床结果表明，重组人粒细胞（rHuG）和粒细胞/巨噬细胞（rHuGM）集落刺激因子（CSF）在自体和异基因骨髓移植（BMT）后增强骨髓植入方面具有活性。在对rHuG-CSF和rHuGM-CSF的前瞻性对照临床试验的多项分析中，已观察到发病率和成本降低以及生存率提高。有理由希望，对这些细胞因子和其他细胞因子体内生物学的更深入了解将进一步降低与自体和异基因BMT相关的发病率和死亡率。这些进展可能会显著拓宽适合BMT治疗的疾病谱。
